OUR SERVICES

We support your viral vector vaccine or gene therapy product development

From pre-clinical to cGMP manufacturing

Exoscan

Process Analysis

We carry out an in-depth review of your current process and its clinical and commercial potential within 8 weeks.

The comprehensive development plan identifies areas for optimization that can fast-track the clinical phase, prepare for competitive commercial launch and act as a financial roadmap for fundraising or board endorsement. 

  • EProcess and data analysis
  • ERisk and gap identification
  • ETechnology comparison and selection
  • ECost modelling

Process Design

& Development

At Exothera, we accelerate the development of new viral vector treatments at every step from process development and optimization to scale-up for manufacturing.

We create custom-made bioproduction programs designed to use the latest technologies for both adherent and suspension cell culture.

Our Design of Experiment (DoE) aims to achieve cost-effectiveness and high performance viral manufacturing that is tailored to the requirements of our customer’s particular therapy. 

  • EPlasmid design and production*
  • EUSP and DSP process optimization and development
  • EAnalytical transfer, bridging and development*
  • ECell line and media optimization / re-selection*
  • EManufacturing of non-GMP and toxicology materials
  • EProcess scale-up
  • EFormulation development*
  • EDispensing into vials
  • EStorage and product delivery

GMP Manufacturing

At Exothera, we have extensive GMP, Quality Control (QC) and Quality Assurance (QA) experience. Our 2 GMP commercial-scale factories cover 8,600 m² allowing us to produce tailored and fully supported GMP products.

We partner with you to provide manufacturing capabilities for clinical & commercial needs using a range of scalable platforms to suit your therapeutic.

Get access to bioproduction capacity and expertise to deliver complex projects more quickly and cost-effectively 

  • EAdherence platform: up to 2 X 600m²
  • ESuspension platform: 2 x 2000L
  • ECMC support
  • EGMP banking: MCB, MVS, WCB and WVS
  • EGMP manufacturing, testing and release services
  • EFill & finish
  • EStorage
  • EStability studies on Drug Substance and Drug Product
  • EWe take in charge* HQ Grade or GMP Plasmid manufacturing

* supported in whole or in part by partner company

Exoscan

Process Analysis

We carry out an in-depth review of your current process and its clinical and commercial potential within 8 weeks.

The comprehensive development plan identifies areas for optimization that can fast-track the clinical phase, prepare for competitive commercial launch and act as a financial roadmap for fundraising or board endorsement. 

  • EProcess and data analysis
  • ERisk and gap identification
  • ETechnology comparison and selection
  • ECost modelling

Process Design

& Development

At Exothera, we accelerate the development of new viral vector treatments at every step from process development and optimization to scale-up for manufacturing.

We create custom-made bioproduction programs designed to use the latest technologies for both adherent and suspension cell culture.

Our Design of Experiment (DoE) aims to achieve cost-effectiveness and high performance viral manufacturing that is tailored to the requirements of our customer’s particular therapy. 

  • EPlasmid design and production*
  • EUSP and DSP process optimization and development
  • EAnalytical transfer, bridging and development*
  • ECell line and media optimization / re-selection*
  • EManufacturing of non-GMP and toxicology materials
  • EProcess scale-up
  • EFormulation development*
  • EDispensing into vials
  • EStorage and product delivery

GMP Manufacturing

At Exothera, we have extensive GMP, Quality Control (QC) and Quality Assurance (QA) experience. Our 2 GMP commercial-scale factories cover 8,600 m² allowing us to produce tailored and fully supported GMP products.

We partner with you to provide manufacturing capabilities for clinical & commercial needs using a range of scalable platforms to suit your therapeutic.

Get access to bioproduction capacity and expertise to deliver complex projects more quickly and cost-effectively 

  • EAdherence platform: up to 2 X 600m²
  • ESuspension platform: 2 x 2000L
  • ECMC support
  • EGMP banking: MCB, MVS, WCB and WVS
  • EGMP manufacturing, testing and release services
  • EFill & finish
  • EStorage
  • EStability studies on Drug Substance and Drug Product
  • EWe take in charge* HQ Grade or GMP Plasmid manufacturing

* supported in whole or in part by partner company